The discovery of the intersection between SUMO1 and SUMO2 modification switch of both STUB1 and KAP1 sheds new light on the regulation of EBV latency and lytic replication, which provides a potential therapeutic target against EBV-associated cancers. This evidence concerns the gene STUB1 and cancer.